390
Participants
Start Date
May 31, 2006
Primary Completion Date
August 31, 2008
Study Completion Date
August 31, 2008
velafermin
administered intravenously as 100mL single dose over 15 minutes on day 1
placebo
administered intravenously as 100mL single dose over 15 minutes on day 1
Cornell Medical Center, New York
Biomedical Research Alliance of New York, New York
Biomedical Research Alliance of New York, The Bronx
Fox Chase-Temple Bone Marrow Transplant Program, Philadelphia
Wake Forest University Health Sciences, Winston-Salem
University of North Carolina, Chapel Hill
Duke University Medical Center, Durham
Medical University of South Carolina Hollings Cancer Center, Charleston
Emory University, Atlanta
University Hospitals of Cleveland, Cleveland
St. Francis Hospital and Health Centers, Beech Grove
Indiana University Cancer Center, Indianapolis
Wayne State University, Detroit
University of Iowa Hospitals and Clinics, Iowa City
Medical College of Wisonsin, Milwaukee
MAYO Clinic, Rochester
Northwestern University, Chicago
Rush University Medical Center, Chicago
University of Kansas Medical Center, Kansas City
Louisiana State University Health Science Center, Shreveport
University of Arkansas for Medical Sciences, Little Rock
University of Oklahoma, Oklahoma City
Baylor University Medical Center, Dallas
University of Colorado Health Sciences Center, Aurora
Rocky Mountain Blood and Marrow Transplant Program, Denver
Research Facility, La Jolla
Scripps Green Medical Center, La Jolla
Alta Bates Comprehensive Cancer Center, Berkley
Legacy Good Samaritan Hospital and Cancer Center, Portland
Oregon Health and Science University, Portland
Cancer Center at Hackensack University Medical Center, Hackensack
Roger Williams Medical Center, Providence
University of Texas Health Science Center, San Antonio
Lead Sponsor
CuraGen Corporation
INDUSTRY